
Coiled Therapeutics enrolls patients for new softgel cancer drug trial to improve absorption and dosing.
Coiled Therapeutics has enrolled six patients into two dosing groups testing a reformulated version of its cancer drug AO-252, designed to better cross the brain and block the cancer-driving protein TACC3. The new lipid-based softgel aims to provide ...





